Molecular Partners (MOLN) Competitors

uniQure (NASDAQ:QURE) and Molecular Partners (NASDAQ:MOLN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, community ranking, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment.

Which has preferable valuation and earnings, QURE or MOLN?

Molecular Partners has lower revenue, but higher earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$28.59M	29.92	-$308.48M	-$4.96	-3.54
Molecular Partners	$6.00M	36.58	-$69.04M	-$2.15	-2.53

Does the media favor QURE or MOLN?

In the previous week, uniQure had 4 more articles in the media than Molecular Partners. MarketBeat recorded 5 mentions for uniQure and 1 mentions for Molecular Partners. uniQure's average media sentiment score of 0.37 beat Molecular Partners' score of 0.00 indicating that uniQure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
uniQure	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Molecular Partners	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do insiders and institutionals hold more shares of QURE or MOLN?

78.8% of uniQure shares are held by institutional investors. Comparatively, 26.5% of Molecular Partners shares are held by institutional investors. 4.7% of uniQure shares are held by insiders. Comparatively, 5.9% of Molecular Partners shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Which has more risk & volatility, QURE or MOLN?

uniQure has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Comparatively, Molecular Partners has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.

Is QURE or MOLN more profitable?

uniQure has a net margin of -837.80% compared to Molecular Partners' net margin of -1,043.01%. Molecular Partners' return on equity of -39.31% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-837.80%	-188.82%	-32.17%
Molecular Partners	-1,043.01%	-39.31%	-35.46%

Do analysts rate QURE or MOLN?

uniQure currently has a consensus target price of $33.88, suggesting a potential upside of 93.02%. Given uniQure's higher possible upside, equities analysts plainly believe uniQure is more favorable than Molecular Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00
Molecular Partners	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00

Does the MarketBeat Community believe in QURE or MOLN?

uniQure received 641 more outperform votes than Molecular Partners when rated by MarketBeat users. Likewise, 70.67% of users gave uniQure an outperform vote while only 46.15% of users gave Molecular Partners an outperform vote.

Company	Underperform	Outperform
uniQure	Outperform Votes 653 70.67%	Underperform Votes 271 29.33%
Molecular Partners	Outperform Votes 12 46.15%	Underperform Votes 14 53.85%

Summary

uniQure beats Molecular Partners on 11 of the 19 factors compared between the two stocks.